Participation Is Not Reform: Why 340B Discounts Should Follow the Patient

The 340B Drug Pricing Program is under growing scrutiny, and maintaining the status quo is unrealistic.However, the new ASCO policy position 1 to increase participation in 340B is not reform.Expanding institutional access to 340B revenue streams without restructuring incentives should not be mistaken for meaningful change.The goal should be rebuilding 340B around patients, accountability, transparency, and lower cost care delivery-and ensuring that vulnerable Americans, not hospitals, receive the discounts.